Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls

Kroksveen, Ann Cathrine; Guldbrandsen, Astrid; Vedeler, C. A.; Myhr, Kjell–Morten; Opsahl, Jill A.; Berven, Frode S.

doi:10.1111/ane.12029

Cited by 66 publications

(81 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with multiple sclerosis, two-dimensional fluorescence difference in-gel electrophoresis followed by mass spectrometry has shown that the determination of DBP in cerebrospinal fluid could serve as a specific diagnostic biomarker of progressive disease [45]. In addition, proteomics studies have reported decreased DBP levels in cerebrospinal fluid in patients with relapsing-remitting multiple sclerosis in comparison with subjects with other neurological diseases [46].…”

Section: Urinary Vitamin D Binding Proteinmentioning

confidence: 99%

Behind the scenes of vitamin D binding protein: More than vitamin D binding

Delanghe

Speeckaert

2015

Best Practice & Research Clinical Endocrinology & Metab

145

124

View full text Add to dashboard Cite

Section: Urinary Vitamin D Binding Proteinmentioning

confidence: 99%

Behind the scenes of vitamin D binding protein: More than vitamin D binding

Delanghe

Speeckaert

2015

Best Practice & Research Clinical Endocrinology & Metab

145

124

View full text Add to dashboard Cite

“…Indeed, relative decreases have been reported in NPR RNA levels in rat brain after cerebral ischemia (Kim et al, 2002) and in a mesencephalic dopaminergic neuronal culture model of PD (Anantharam et al, 2007). Furthermore, decreased CSF NPR levels have been reported in multiple sclerosis (Kroksveen et al, 2012). Although a relative upregulation of NPR RNA in cardiac muscle has been reported after myocardial infarction (Andersson et al, 2006), the expression of NPR RNA in brain is far higher than that seen in other organs (Dodds et al, 1997).…”

Section: Discussionmentioning

confidence: 99%

Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease

Bilousova

Taylor

Emirzian

et al. 2015

Neurobiology of Disease

View full text Add to dashboard Cite

Neuronal pentraxin receptor (NPR) is a synaptic protein implicated in AMPA receptor trafficking at excitatory synapses. Since glutamate neurotransmission is disrupted in Alzheimer’s disease (AD), NPR levels measured from plasma represent a potential biomarker for synaptic dysfunction associated with AD. We sought to determine the relationship between AD pathology and brain and plasma NPR levels by examining age-associated NPR levels in these compartments in a transgenic APP/PS1 rat model of AD. NPR levels in cortical homogenate were similar in wild-type (Wt) and APP/PS1 rats at 3 months of age (prior to Aβ plaque deposition), but significantly increased in APP/PS1 rats by 9 and 18-20 months of age (after the onset of plaque deposition). These age-dependent differences were driven by proportional increases in NPR in membrane-associated cortical fractions. Genotype-related differences in NPR expression were also seen in the hippocampus, which exhibits significant Aβ pathology, but not in the cerebellum, which does not. Plasma analyses revealed increased levels of a 26 kDa NPR fragment in APP/PS1 rats relative to Wt rats by 18-20 months of age, which correlated with the levels of full-length NPR in cortex. Our findings indicate that cerebral accumulation of NPR and Aβ occurs with similar temporal and regional patterns in the APP/PS1 model, and suggest that a 26 kDa plasma NPR fragment may represent a peripheral biomarker of this process.

show abstract

“…Chymotrypsin activity was inhibited by adding 2 mM CaCl2 and the proteins were digested to peptides over night at 37°C using trypsin (Sequencing Grade Modified Trypsin, Promega) at a protein:trypsin ratio of 1:50. Each sample was acidified using 10% FA to quench the digestion activity, desalted and concentrated on an Oasis HLB μElution Plate (Waters) as previously described [14] followed by drying the sample completely in a vacuum concentrator.…”

Section: Methodsmentioning

confidence: 99%

“…The pooled patient iTRAQ-data was searched using the Spectrum Mill software package v4.0 (Agilent Technologies, Santa Clara, CA) using the same settings as previously described [14]. MS/MS data was searched against the SwissProtKB database (release 2011_10) with a precursor mass tolerance of 15 ppm, and a product mass tolerance 0.7 Da.…”

Section: Methodsmentioning

confidence: 99%

“…A qualitative protein comparison study between 14 patients did indicate AC fluid protein profiles to be relatively homogenous between patients. Label-free quantitative proteomics by measured precursor intensity is a well-established method for obtaining relative quantitative measurements of a large number of proteins between samples [14]. Quantitative proteomics by Isobaric tag for relative and absolute quantification (iTRAQ) [15] allows for extensive fractionation at the peptide level of samples pooled after labelling without loosing analytical reproducibility.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quantitative proteomics comparison of arachnoid cyst fluid and cerebrospinal fluid collected perioperatively from arachnoid cyst patients

Berle

Kroksveen

Garberg

et al. 2013

Fluids Barriers CNS

View full text Add to dashboard Cite

BackgroundThere is little knowledge concerning the content and the mechanisms of filling of arachnoid cysts. The aim of this study was to compare the protein content of arachnoid cysts and cerebrospinal fluid by quantitative proteomics to increase the understanding of arachnoid cysts.MethodsArachnoid cyst fluid and cerebrospinal fluid from five patients were analyzed by quantitative proteomics in two separate experiments.In a label-free experiment arachnoid cyst fluid and cerebrospinal fluid samples from individual patients were trypsin digested and analyzed by Orbitrap mass spectrometry in a label-free manner followed by data analysis using the Progenesis software.In the second proteomics experiment, a patient sample pooling strategy was followed by MARS-14 immunodepletion of high abundant proteins, trypsin digestion, iTRAQ labelling, and peptide separation by mix-phase chromatography followed by Orbitrap mass spectrometry analysis. The results from these analyzes were compared to previously published mRNA microarray data obtained from arachnoid membranes.ResultsWe quantified 348 proteins by the label-free individual patient approach and 1425 proteins in the iTRAQ experiment using a pool from five patients of arachnoid cyst fluid and cerebrospinal fluid. This is by far the largest number of arachnoid cyst fluid proteins ever identified, and the first large-scale quantitative comparison between the protein content of arachnoid cyst fluid and cerebrospinal fluid from the same patients at the same time. Consistently in both experiment, we found 22 proteins with significantly increased abundance in arachnoid cysts compared to cerebrospinal fluid and 24 proteins with significantly decreased abundance. We did not observe any molecular weight gradient over the arachnoid cyst membrane. Of the 46 proteins we identified as differentially abundant in our study, 45 were also detected from the mRNA expression level study. None of them were previously reported as differentially expressed. We did not quantify any of the proteins corresponding to gene products from the ten genes previously reported as differentially abundant between arachnoid cysts and control arachnoid membranes.ConclusionsFrom our experiments, the protein content of arachnoid cyst fluid and cerebrospinal fluid appears to be similar. There were, however, proteins that were significantly differentially abundant between arachnoid cyst fluid and cerebrospinal fluid. This could reflect the possibility that these proteins are affected by the filling mechanism of arachnoid cysts or are shed from the membranes into arachnoid cyst fluid. Our results do not support the proposed filling mechanisms of oncotic pressure or valves.

show abstract

Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls

Cited by 66 publications

References 38 publications

Behind the scenes of vitamin D binding protein: More than vitamin D binding

Behind the scenes of vitamin D binding protein: More than vitamin D binding

Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease

Quantitative proteomics comparison of arachnoid cyst fluid and cerebrospinal fluid collected perioperatively from arachnoid cyst patients

Contact Info

Product

Resources

About